HenryEWalkerDWiedmeierChristensenRD. Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. Am J Med Genet A. 2007;143:42-50.
2.
XuGNaganoMKanezakiR. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003;102:2960-2968.
RhoderickJBradshawW. Transient myeloproliferative disorder in a newborn with Down syndrome. Adv Neonatal Care. 2008;8:208-218.
5.
RoyARobertsINortonAVyasP. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br J Haematol. 2009;147:3-12.
6.
HealdBHildenJZbukK. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome. Nat Clin Pract Oncol. 2007;4:433-438.
7.
HironoKMiuraMKaneganeH. Hepatocyte growth factor in transient myeloproliferative disorder of Down syndrome. Pediatr Int. 2009;51:754-755.
8.
AhmedMSternbergAHallG. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480-2489.
9.
ApollonskyNShendeAOuansafiIBrodyJAtlasMAygunB. Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes. J Pediatr Hematol Oncol. 2008;30:860-864.
10.
HojoSTsukimoriKKitadeS. Prenatal sonographic findings and hematological abnormalities in fetuses with transient abnormal myelopoiesis with Down syndrome. Prenat Diagn. 2007;27:507-511.
11.
CrazeJLHarrisonGWheatleyKHannIMChessellsJM. Improved outcome of acute myeloid leukaemia in Down’s syndrome. Arch Dis Child. 81:32-37.
